Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGE025 add-on therapy in refractory chronic spontaneous urticaria (China, phase 3)
CTR20160917Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Novartis. Started Feb 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20160917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160917.